Dai L Y, Zhao J X
Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100091, China.
Zhonghua Yi Xue Za Zhi. 2022 Oct 11;102(37):2909-2913. doi: 10.3760/cma.j.cn112137-20220224-00394.
With the in-depth research on treatment drugs of rheumatoid arthritis (RA), a variety of disease modifying anti-rheumatic drugs (DMARDs) have been approved for the treatment of RA. By now methotrexate (MTX) is still the anchor drug for RA treatment. The 2019 European League Against Rheumatism (EULAR) and 2021 American College of Rheumatology (ACR) recommendations for RA management both point out that for newly diagnosed RA patients, MTX monotherapy should be used as the first choice, which shows the importance of MTX monotherapy in DMARDs naïve RA. This paper mainly reviews the relevant researches on MTX in the treatment of RA in recent years, especially the relevant literature on the use of MTX monotherapy in initial treatment of RA. We summarize the development history, efficacy, treatment and adverse reactions of MTX to recognize the importance of MTX in the treatment of RA and the feasibility of MTX monotherapy.
随着对类风湿关节炎（RA）治疗药物的深入研究，多种改善病情抗风湿药（DMARDs）已被批准用于治疗RA。到目前为止，甲氨蝶呤（MTX）仍然是RA治疗的基础药物。2019年欧洲抗风湿病联盟（EULAR）和2021年美国风湿病学会（ACR）的RA管理建议均指出，对于新诊断的RA患者，应首选MTX单药治疗，这表明MTX单药治疗在初治RA的DMARDs治疗中的重要性。本文主要综述近年来MTX治疗RA的相关研究，尤其是MTX单药用于RA初始治疗的相关文献。我们总结MTX的发展历程、疗效、治疗方法及不良反应，以认识MTX在RA治疗中的重要性及MTX单药治疗的可行性。
